3 completed, 1 terminated, 1 unknown. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 3, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Myoclonic Epilepsies, Progressive: new trials by email Literature Review of Myoclonic Epilepsies, Progressive trials Research Report on Myoclonic Epilepsies, Progressive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease Vatiquinone - Inherited Mitochondrial Disease | Phase 3 | Completed | PTC Therapeutics | 101 | 2022-06-22 | 2025-12-22 |
| A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Vatiquinone, Placebo - Mitochondrial Diseases, Drug Resistant Epilepsy | Phase 2 / Phase 3 | Terminated | PTC Therapeutics | 68 | 2020-09-28 | 2026-03-31 |
| Intravenous Immunoglobulin for Unverricht-Lundborg Disease. Intravenous immunoglobulin - Unverricht-Lundborg Disease | Phase 3 | Unknown | Azienda Socio Sanitaria Territoriale di Mantova | 1 | 2015-12-09 | 2017-11-27 |
| Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults Brivaracetam 25 mg, Brivaracetam 50 mg, Placebo - Unverricht-Lundborg Disease | Phase 3 | Completed | UCB Pharma SA | 50 | 2006-11-01 | 2015-05-18 |
| Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults Placebo, BRV 2.5 mg, BRV 25 mg - Unverricht-Lundborg Disease | Phase 3 | Completed | UCB Pharma | 56 | 2006-11-01 | 2023-05-31 |
Unverricht-Lundborg Syndrome (3) · Diffuse Cerebral Sclerosis of Schilder (2) · Drug Resistant Epilepsy (2) · Leigh Disease (2) · MELAS Syndrome (2) · MERRF Syndrome (2) · Myoclonus (2) · Mitochondrial Diseases (1) · Mitochondrial Encephalomyopathies (1) · Mitochondrial encephalopathy (1) · Nerve Degeneration (1) · Pontocerebellar Hypoplasia Type 6 (1) · Seizures (1) · Status Epilepticus (1)
Brain Diseases (5) · Central Nervous System Diseases (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Epilepsies, Myoclonic (5) · Epilepsy (5) · Epilepsy, Generalized (5) · Epileptic Syndromes (5) · Genetic Diseases, Inborn (5) · Nervous System Diseases (5) · Heredodegenerative Disorders, Nervous System (3) · Neurodegenerative Diseases (3) · Neurologic Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Autoimmune Diseases (2)
alpha-tocotrienol quinone (2) · brivaracetam (2) · Immunoglobulins, Intravenous (1)
PTC Therapeutics (2) · Azienda Socio Sanitaria Territoriale di Mantova (1) · UCB Pharma (1) · UCB Pharma SA (1)
France (4) · Italy (3) · United States (3) · Canada (2) · Finland (2) · Japan (2) · Poland (2) · Spain (2) · Sweden (2) · Tunisia (2) · United Kingdom (2) · Israel (1) · Netherlands (1) · Reunion (1) · Russia (1)
2017 (1)